Hans Biomed Corp banner
H

Hans Biomed Corp
KOSDAQ:042520

Watchlist Manager
Hans Biomed Corp
KOSDAQ:042520
Watchlist
Price: 30 200 KRW -5.33% Market Closed
Market Cap: ₩408.6B

Hans Biomed Corp
Net Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hans Biomed Corp
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
H
Hans Biomed Corp
KOSDAQ:042520
Net Income
-₩28.2B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Income
₩1T
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
22%
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Net Income
-₩15.7B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Net Income
-₩32.6B
CAGR 3-Years
-27%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Net Income
₩145.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
61%
A
ABL Bio Inc
KOSDAQ:298380
Net Income
-₩37.9B
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Hans Biomed Corp
Glance View

Market Cap
408.6B KRW
Industry
Biotechnology

Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-10-09. The firm mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.

Intrinsic Value
33 765.08 KRW
Undervaluation 11%
Intrinsic Value
Price ₩30 200
H

See Also

What is Hans Biomed Corp's Net Income?
Net Income
-28.2B KRW

Based on the financial report for Dec 31, 2025, Hans Biomed Corp's Net Income amounts to -28.2B KRW.

What is Hans Biomed Corp's Net Income growth rate?
Net Income CAGR 3Y
-2%

Over the last year, the Net Income growth was -223%. The average annual Net Income growth rates for Hans Biomed Corp have been -2% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett